EMA Authorised: Vegzelma (bevacizumab) — Celltrion Healthcare Hungary Kft.

View source ↗

Summary

EMA authorised Vegzelma, a bevacizumab biosimilar from Celltrion Healthcare Hungary Kft., for multiple cancers including colorectal, breast, ovarian, fallopian …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Colorectal Cancer
• Fallopian Tube Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Peritoneal Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Vegzelma (bevacizumab)

Snippet

Status: Authorised. Therapeutic area: Colorectal Neoplasms;Breast Neoplasms;Ovarian Neoplasms;Fallopian Tube Neoplasms;Peritoneal Neoplasms;Carcinoma, Non-Small-Cell Lung;Carcinoma, Renal Cell;Uterine Cervical Neoplasms. MAH: Celltrion Healthcare Hungary Kft.. Decision date: 18/12/2025